Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide.

Article Details

Citation

Copy to clipboard

Kother M, Schindler J, Oette K, Berthold F

Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide.

In Vivo. 1992 Mar-Apr;6(2):219-21.

PubMed ID

1525342 [ View in PubMed

]

Abstract

In patients undergoing high-dose ifosfamide treatment tubular nephrotoxicity with hypophosphatemia has been described. Long-lasting hypophosphatemia may be associated with bone disease including rickets. Serum osteocalcin is considered a sensitive marker for reduced osteoblast activity and bone formation. In our study we determined osteocalcin serum levels in 11 children with cancer and chemotherapy, comparing them with fractional reabsorption of phosphate, aminoaciduria and a1-microglobulin excretion. A decrease of serum levels of osteocalcin and serum phosphate during chemotherapy was found. Progressive hyperaminoaciduria, a1-microglobulin loss and a low fractional reabsorption of phosphate were also detected during chemotherapy. All parameters tended to become normal after treatment. We conclude that serum osteocalcin levels may decrease soon after the initiation of chemotherapy, indicating low osteoblast activity, probably as a result of phosphate loss. Patients with decreased osteocalcin levels may therefore be at risk for osteoporosis.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Ifosfamide	Approved	Phosphate	decreased	Ifosfamide decreases the level of Phosphate in the blood

Pharmaco-proteomics

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome
Ifosfamide	Approved	BGLAP	632	decreased	Ifosfamide results in decreased expression of BGLAP protein	1q22